Caribou Biosciences, Inc. (CRBU)

Over the past six months, Caribou Biosciences' stock has experienced several notable events. As of November 25, 2025, the share price was $1.87, a decline from $2.02 on November 26, 2024. The stock decreased by 18.57% in the past month and 0.65% over the last three months leading up to November 14, 2025. Caribou Biosciences reported its Q3 2025 financial results on November 12, 2025, including a loss and missing revenue estimates. On November 14, 2025, Caribou Biosciences reported positive ANTLER Phase 1 results. In June 2024, the stock tumbled 30% following the release of Phase 1 data from its ANTLER study for CB-010 and an Evercore downgrade. In July 2024, the company admitted it was running out of cash and had to curtail research activities. In March 2025, Caribou Biosciences reported its Q4 and full-year 2024 financial results, anticipating two clinical data disclosures in the first half of 2025. In June 2025, the stock was trading around $1.26. As of June 30, 2025, Caribou had $183.9 million in cash, cash equivalents, and marketable securities. In July 2025, the stock experienced a 47% increase in share price after a year of 1.3% losses. Non-recurring, non-cash impairment charges of $21.3 million were reported for the three months ended June 30, 2025.

The provided search results do not contain specific information regarding demand seasonality for Caribou Biosciences, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by medical need and treatment efficacy rather than typical seasonal consumer patterns.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for severe human diseases, particularly hematologic malignancies and autoimmune diseases. The company operates within the Healthcare sector and the Biotechnology industry, leveraging its CRISPR-based genome-editing platform, including its CRISPR hybrid RNA-DNA (chRDNA) technology, to develop off-the-shelf cell therapies designed for enhanced precision, efficacy, and safety. Its major product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy in Phase 1 clinical trials; CB-011, an anti-BCMA allogeneic CAR-T cell therapy in Phase 1 clinical trials; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy also in Phase 1 clinical trials.

Caribou Biosciences, Inc. is headquartered in Berkeley, California, United States, and engages in the development of its cell therapies in the United States and internationally.

Information directly detailing Caribou Biosciences' brand reputation in the past year is not explicitly available. An Evercore analyst report questioned the effectiveness of CB-010, leading to a stock price drop and a downgrade, negatively impacting the company's reputation. The company's admission of running out of cash and curtailing research activities also likely damaged investor confidence and reputation. Positive clinical data readouts and encouraging efficacy observations for CB-011 could contribute positively to its reputation. Analyst ratings suggest a somewhat positive outlook from the financial community despite past challenges.

Caribou Biosciences has a mixed ownership structure. Institutional investors own approximately 20.54% to 27.33% of the company's stock, with major holders including Pfizer Inc and Vanguard Group Inc. Individual investors hold approximately 42% to 64.52% ownership. Insiders own approximately 8.15% of the stock, with CEO Rachel Haurwitz having meaningful ownership. Private equity firms hold a 5.0% stake.